Greg received his bachelor's degree in Microbiology from Brigham Young University, where he developed a new class of influenza inhibitors. He completed his PhD degree at UCSF in Martin Kampmann's Lab. In the Kampmann lab, he studied how the V337M tau mutation perturbs the differentiation of iPSC-derived neurons. Greg works with the Clelland Lab at the Edward and Pearl Fein Memory and Aging Center to develop new methods for screening nanoparticle-delivery systems for gene-editing therapies.
Clelland Lab
The Clelland Lab is devoted to developing novel therapies for neurodegenerative diseases using CRISPR gene editing technology. We are focusing first on frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (AD) caused by single gene mutations, since this class of monogenic neurodegenerative disease is likely to be cured by gene correction.